Neurodegenerative Disorder Therapeutics Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global neurodegenerative disorder therapeutics market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the neurodegenerative disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Neurodegenerative Disorder Therapeutics market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider neurodegenerative disorder therapeutics market, and compares it with other markets.
Scope
Markets Covered: 1) By Indication Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Other Indication Types; 2) By Drug Type: N- methyl- D- aspartate Receptor; Selective Serotonin Reuptake Inhibitor; Dopamine Inhibitors; Other Drug Types; 3) By Distribution: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Biogen; Pfizer; Novartis; Sanofi; Teva Pharmaceutical
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the neurodegenerative disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Neurodegenerative Disorder Therapeutics market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider neurodegenerative disorder therapeutics market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The neurodegenerative disorder therapeutics market section of the report gives context. It compares the neurodegenerative disorder therapeutics market with other segments of the neurodegenerative disorder therapeutics market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, neurodegenerative disorder therapeutics indicators comparison.
Scope
Markets Covered: 1) By Indication Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Other Indication Types; 2) By Drug Type: N- methyl- D- aspartate Receptor; Selective Serotonin Reuptake Inhibitor; Dopamine Inhibitors; Other Drug Types; 3) By Distribution: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Biogen; Pfizer; Novartis; Sanofi; Teva Pharmaceutical
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Neurodegenerative Disorder Therapeutics Market Characteristics26. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market27. Neurodegenerative Disorder Therapeutics Market Trends And Strategies28. Neurodegenerative Disorder Therapeutics Market Future Outlook and Potential Analysis
3. Neurodegenerative Disorder Therapeutics Market Size And Growth
4. Neurodegenerative Disorder Therapeutics Market Segmentation
5. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis
6. Asia-Pacific Neurodegenerative Disorder Therapeutics Market
7. China Neurodegenerative Disorder Therapeutics Market
8. India Neurodegenerative Disorder Therapeutics Market
9. Japan Neurodegenerative Disorder Therapeutics Market
10. Australia Neurodegenerative Disorder Therapeutics Market
11. Indonesia Neurodegenerative Disorder Therapeutics Market
12. South Korea Neurodegenerative Disorder Therapeutics Market
13. Western Europe Neurodegenerative Disorder Therapeutics Market
14. UK Neurodegenerative Disorder Therapeutics Market
15. Germany Neurodegenerative Disorder Therapeutics Market
16. France Neurodegenerative Disorder Therapeutics Market
17. Eastern Europe Neurodegenerative Disorder Therapeutics Market
18. Russia Neurodegenerative Disorder Therapeutics Market
19. North America Neurodegenerative Disorder Therapeutics Market
20. USA Neurodegenerative Disorder Therapeutics Market
21. South America Neurodegenerative Disorder Therapeutics Market
22. Brazil Neurodegenerative Disorder Therapeutics Market
23. Middle East Neurodegenerative Disorder Therapeutics Market
24. Africa Neurodegenerative Disorder Therapeutics Market
25. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The neurodegenerative disorder therapeutics market consists of sales of neurodegenerative disorder therapeutics products and related services for neurodegenerative disorders. Neurodegenerative disorder is a range of incurable conditions that primarily affect the neurons of human brain and results in progressive degeneration or death of nerve cells. The neurodegenerative disorder therapeutics deals with the manufacturing and development of drugs and treatment that stops or slows down the neurodegenerative processes of diseases such as Parkinson’s, Alzheimer’s, Huntington’s and other neurodegenerative disorders.The global neurodegenerative disorder therapeutics market was worth $13.35 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 8.12% and reach $18.23 billion by 2023.
The neurodegenerative disorder therapeutics market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America was the largest region in 2019 and Europe was the fastest growing region in 2019.
The neurodegenerative disorder therapeutics market covered in this report is segmented by indication type into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease, other indications. It is also segmented by drug type into n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, others and by distribution into hospital pharmacy, retail pharmacy, online pharmacy.
Increased prevalence of neurodegenerative among the global population contributes to the growth of neurodegenerative disorder therapeutics market. The increase in the number of geriatric population, attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects in 2017, the number of people above 60 years of age will increase from 962 million in 2017 to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple from 137 million in 2017 to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer disease and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby driving the market.
High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently very few treatments are approved for neurodegenerative disorders. According to a study, researchers found out that between 2002 to 2012, only 244 compounds in 413 clinical trials for Alzheimer’s disease passed through but only one compound was approved. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate at 81%. Moreover, as reported by The New England Journal of Medicine, in 2018, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics have a negative impact on the market, hindering the growth of the market.
Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non- government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market in order to increase their capabilities for research and development activities in order to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, from October 2019, Prevail Therapeutics Inc., a USA based biotechnology company and Lonza, a global supplier of pharma & Biotech and specialty ingredients based in Switzerland, collaborated to develop and manufacture gene therapy programs for patients of neurodegenerative diseases. Similarly, in February 2018, Abbevie, a USA based biopharmaceutical company and Voyager Therapeutics, a clinical stage gene therapy company based in USA, underwent a global strategic collaboration to develop and commercialize treatments for Alzheimer’s disease and other tau-related (a protein) neurodegenerative diseases.
In January 2020, Biogen Inc., an America Biotechnology company acquired a novel clinical stage asset, PF-05251749 alongwith the applications from Pfizer for $75 million. The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS- penetrant regulator that has the potential to treat behavioral and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc., is a multinational pharmaceutical company based in the USA.
Major players in the market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen
- Pfizer
- Novartis
- Sanofi
- Teva Pharmaceutical
- UCB
- Hoffmann- La Roche Ltd
- ACADIA Pharmaceuticals Inc.
- Lundeck A/S
- Boehringer Ingeiheim International GmbH
- Merck Serono
- Orion Pharma Ltd
- Mitsubishi Tanabe Pharma America
- Allergan
- GlaxoSmith Kline PLC
- AbbVie
- Eli lilly
- Celgene
- Neuro- Hitech Inc.
- Bayer Schering Pharma AG
- Amarin Corporation
- AstraZeneca
- Alector
- Yumanity Therapeutics
- Yangtze River Pharmaceutical Group
- Chongqing Zein Pharmaceutical
- Eisai
Methodology
LOADING...
